The Acute Renal Failure (ARF) (Acute Kidney Injury) drugs in development market research report provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Acute Renal Failure (ARF) (Acute Kidney Injury). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued products.

GlobalData tracks 96 drugs in development for Acute Renal Failure (ARF) (Acute Kidney Injury) by 88 companies/universities/institutes. The top development phase for Acute Renal Failure (ARF) (Acute Kidney Injury) is preclinical with 60 drugs in that stage. The Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline has 91 drugs in development by companies and five by universities/ institutes. Some of the companies in the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline products market are: Johnson & Johnson, Elicio Therapeutics and Q BioMed.

The key targets in the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline products market include Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1), 2 Amino 3 Carboxymuconate 6 Semialdehyde Decarboxylase (Picolinate Carboxylase or ACMSD or EC 4.1.1.45), and Free Radical.

The key mechanisms of action in the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline product include Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or with four drugs in Preclinical. The Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline products include 12 routes of administration with the top ROA being Intravenous and 15 key molecule types in the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline products market including Small Molecule, and Recombinant Protein.

Acute Renal Failure (ARF) (Acute Kidney Injury) overview

Acute renal failure occurs when the kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases, and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure, and kidney diseases. Treatment includes antibiotics and diuretics.

For a complete picture of Acute Renal Failure (ARF) (Acute Kidney Injury)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.